Price Sensitive Information

The Meeting of the Board of Directors of Beacon Pharmaceuticals PLC. held on 22nd October, 2025 at 3.30 PM at its Corporate Office, BEACON Business Centre, 9/B/2, Toyenbee Circular Road, Motijneel C/A, Dhaka-1223 to approve the Audited Financial Statements of the Company for the year ended 30th June, 2025 and has taken the following decisions:

Date & time of the 24th AGM : 23rd December, 2025, Tuesday at 11.00 a.m through Hybrid.
Venue of the 24th AGM : Hybrid
Record Date : 16th November, 2025.

Recommended Dividend : 21% Cash Dividend to General Shareholder and No Dividend to Sponsor Shareholder & Directors.

The Board also declared the following financial information:

Financial Information:
Earning Per Share (EPS) : Tk. 4.10
Net Asset Value Per Share (NAVPS) : Tk. 28.86
Net Operating Cash Flow Per Share (NOCFPS) : Tk.6.93

The Comparative statement of financial information in respect of previous year is as follows:

Sl. No.	Pariticulars	Yr. 2024-25	Yr.2023-24
1.	Earning Per Share (EPS)	Tk. 4.10	Tk. 2.26
2.	Net Asset Value Per Share (NAVPS)	Tk. 28.86	Tk. 26.37
3.	Net Operating Cash Flow Per Share (NOCFPS)	Tk. 6.93	Tk. (0.78)

Date : 22-10-2025

By the order of the Board of Directors

BEACON®
Pharmaceuticals PLC
BEACON Business Centre:
9/B/2 Toyenbee Circular Road, Motijheel, Dhaka-1223

S/D
Md. Sahabuddin FCS
Company Secretary

- Hon'ble Shareholders are requested to update the particulars of their BO ID with mailing address, contact number, email ID and 12 Digit Taxpayer's Identification Number (e-TIN) through Depository Participants (DP) before the record date.
- Failure to provide e-TIN to Depository Participants, Tax to be deducted @ 15% instead of 10% (Individual) as per Section 54 of Income Tax Ordinance 1984.